The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Professor Ofri Mosenzon MD, MSc is Professor of Internal Medicine, Endocrinology and Epidemiology at the Hebrew University of Jerusalem Medical School and School of Public Health in Jerusalem, Israel.
She is board certified in internal medicine and endocrinology. She is Director of the Diabetes Clinical Research Center, Diabetes Unit, Department of Endocrinology and Metabolism at Hadassah Hebrew University Hospital.
Professor Mosenzon has been involved in more than 80 clinical trials related to diabetes, obesity, cardiovascular outcome trials (CVOTs), diabetic nephropathy and others. She is part of distinguished academic international groups leading large international CVOTs, including SAVOR-TIMI 53, DECLARE-TIMI 58 and PIONEER 6. She has published widely on a range of diabetes topics, including treatment of diabetes and cardiovascular and renal complications of diabetes. She has presented at many national and international conferences, including American Diabetes Association, Endocrine Society’s annual meeting, American Society of Nephrology, European Renal Association-European Dialysis and Transplant Association, and European Association for the Study of Diabetes Scientific Sessions.
Professor Mosenzon is very involved in developing curriculums for continuing medical education for family physicians in diabetes and lecturing to medical and master’s students. She is Founder and Academic Director of the school of continuing medical education in the faculty of medicine at the Hebrew University of Jerusalem.
Professor Mosenzon has contributed chapters in books relating to diabetes treatment in Israel. She has many (and quickly growing numbers) of original papers, reviews, commentaries and editorials in leading peer-reviewed journals.